# **NIOSH Skin Notation Profile**

## Cyclohexanol





Centers for Disease Control and Prevention National Institute for Occupational Safety and Health This page intentionally left blank.

# **NIOSH Skin Notation Profile**

Cyclohexanol

Naomi L. Hudson

**DEPARTMENT OF HEALTH AND HUMAN SERVICES** Centers for Disease Control and Prevention National Institute for Occupational Safety and Health This document is in the public domain and may be freely copied or reprinted.

## Disclaimer

Mention of any company or product does not constitute endorsement by the National Institute for Occupational Safety and Health (NIOSH). In addition, citations to Web sites external to NIOSH do not constitute NIOSH endorsement of the sponsoring organizations or their programs or products. Furthermore, NIOSH is not responsible for the content of these Web sites.

## **Get More Information**

Find NIOSH products and get answers to workplace safety and health questions:

1-800-CDC-INFO (**1-800-232-4636**) | TTY: 1-888-232-6348 CDC/NIOSH INFO: cdc.gov/info | cdc.gov/niosh Monthly *NIOSH eNews*: cdc.gov/niosh/eNews

## **Suggested Citation**

NIOSH [2020]. NIOSH skin notation profile: cyclohexanol. By Hudson NL. Cincinnati, OH: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, DHHS (NIOSH) Publication No. 2021-101.

DHHS (NIOSH) Publication No. 2021-101

DOI: https://doi.org/10.26616/NIOSHPUB2021101

October 2020

## Foreword

As the largest organ of the body, the skin performs multiple critical functions, such as serving as the primary barrier to the external environment. For this reason, the skin is often exposed to potentially hazardous agents, including chemicals, which may contribute to the onset of a spectrum of adverse health effects ranging from localized damage (such as irritant contact dermatitis and corrosion) to induction of immune-mediated responses (such as allergic contact dermatitis and pulmonary responses) or systemic toxicity (such as neurotoxicity and hepatotoxicity). Understanding the hazards related to skin contact with chemicals is a critical component of modern occupational safety and health programs.

In 2009, the National Institute for Occupational Safety and Health (NIOSH) published *Current Intelligence Bulletin (CIB) 61: A Strategy for Assigning New NIOSH Skin Notations* [NIOSH 2009-147]. This document provides the scientific rationale and framework for the assignment of multiple hazard-specific skin notations (SK) that clearly distinguish between the systemic effects, direct (localized) effects, and immune-mediated responses caused by skin contact with chemicals. The key step within assignment of the hazard-specific SK is the determination of the hazard potential of the substance, or its potential for causing adverse health effects as a result of skin exposure. This determination entails a health hazard identification process that involves use of the following:

- Scientific data on the physicochemical properties of a chemical
- Data on human exposures and health effects
- Empirical data from in vivo and in vitro laboratory testing
- Computational techniques, including predictive algorithms and mathematical models that describe a selected process (such as skin permeation) by means of analytical or numerical methods.

This *Skin Notation Profile* provides the SK assignments and supportive data for cyclohexanol. In particular, this document evaluates and summarizes the literature describing the hazard potential of the substance and its assessment according to the scientific rationale and framework outlined in *CIB 61*. In meeting this objective, this *Skin Notation Profile* intends to inform the audience—mostly occupational health practitioners, researchers, policy- and decision-makers, employers, and workers in potentially hazardous workplaces—so that improved risk-management practices may be developed to better protect workers from the risks of skin contact with the chemicals of interest.

John Howard, M.D. Director, National Institute for Occupational Safety and Health Centers for Disease Control and Prevention This page intentionally left blank.

## Contents

Foreword	iii
Abbreviations	vi
Glossary	viii
Acknowledgments	ix
1 Introduction	1
1.1 General Substance Information	1
1.2 Purpose	1
1.3 Overview of SK Assignment	1
2 Systemic Toxicity from Skin Exposure (SK: SYS)	2
3 Direct Effects on Skin (SK: DIR)	3
4 Immune-mediated Responses (SK: SEN)	4
5 Summary	4
References	5
Appendix: Calculation of the SI Ratio for Cyclohexanol	6
Overview	6
Calculation	7
Appendix References	7

## **Abbreviations**

<b>ACGIH</b> <sup>®</sup>	American Conference of Governmental Industrial Hygienists	
AMU	atomic mass unit	
ATSDR	Agency for Toxic Substances and Disease Registry	
CIB	Current Intelligence Bulletin	
ChE	cholinesterase	
cm <sup>2</sup>	square centimeter(s)	
cm/hr	centimeter(s) per hour	
COR	subnotation of SK: COR indicating the potential for a chemical to be corrosive to the skin following exposure	
<b>DEREK</b> <sup>®</sup>	Deductive Estimation of Risk from Existing Knowledge	
DIR	skin notation indicating the potential for direct effects to the skin following contact with a chemical	
FATAL	subnotation of SK: SYS, indicating the potential for the chemical to be fatal during dermal absorption	
GHS	Globally Harmonized System of Classification and Labelling of Chemicals	
GPMT	guinea pig maximization test	
hr	hour(s)	
IARC	International Agency for Research on Cancer	
ID <sup>(SK)</sup>	skin notation indicating that a chemical has been evaluated, but insufficient data exist to accurately assess the hazards of skin exposure	
IRR	subnotation of SK: DIR indicating the potential for a chemical to be a skin irritant following exposure to the skin	
$k_{aq}$	coefficient in the watery epidermal layer	
$k_p$	skin permeation coefficient	
$k_{pol}$	coefficient in the protein fraction of the stratum corneum	
k <sub>psc</sub>	permeation coefficient in the lipid fraction of the stratum corneum	
LD <sub>50</sub>	dose resulting in 50% mortality in the exposed population	
$\mathrm{LD}_{\mathrm{Lo}}$	dermal lethal dose	
LOAEL	lowest-observed-adverse-effect level	
log K <sub>ow</sub>	base-10 logarithm of a substance's octanol-water partition	
М	molar	
<b>m</b> <sup>3</sup>	cubic meter(s)	
mg	milligram(s)	
mg/cm <sup>3</sup>	milligram(s) per cubic centimeter	
mg/kg	milligram(s) per kilogram body weight	
mg/min	milligram(s) per minute	
mL	milliliter(s)	
MW	molecular weight	
NIOSH	National Institute for Occupational Safety and Health	
NOAEL	no-observed-adverse-effect level	

NTP	National Toxicology Program
OEL	occupational exposure limit
OSHA	Occupational Safety and Health Administration
REL	recommended exposure limit
RF	retention factor
SEN	skin notation indicating the potential for immune-mediated reactions following exposure of the skin
SI ratio	ratio of skin dose to inhalation dose
SK	skin notation
<del>SK</del>	skin notation indicating that the reviewed data did not identify a health risk associated with skin exposure
$S_W$	solubility in water
SYS	skin notation indicating the potential for systemic toxicity following exposure of the skin
US EPA	United States Environmental Protection Agency
w/v	weight/volume

## Glossary

**Absorption**—The transport of a chemical from the outer surface of the skin into both the skin and systemic circulation (including penetration, permeation, and resorption).

Acute exposure—Contact with a chemical that occurs once or for only a short period of time.

**Cancer**—Any one of a group of diseases that occur when cells in the body become abnormal and grow or multiply out of control.

**Contaminant**—A chemical that is (1) unintentionally present within a neat substance or mixture at a concentration less than 1.0% or (2) recognized as a potential carcinogen and present within a neat substance or mixture at a concentration less than 0.1%.

Cutaneous (or percutaneous)—Referring to the skin (or through the skin).

Dermal—Referring to the skin.

Dermal contact—Contact with (touching) the skin.

**Direct effects**—Localized, non-immune-mediated adverse health effects on the skin, including corrosion, primary irritation, changes in skin pigmentation, and reduction/disruption of the skin barrier integrity, occurring at or near the point of contact with chemicals.

**Immune-mediated responses**—Responses mediated by the immune system, including allergic responses.

**Sensitization**—A specific immune-mediated response that develops following exposure to a chemical, which, upon re-exposure, can lead to allergic contact dermatitis (ACD) or other immune-mediated diseases such as asthma, depending on the site and route of re-exposure.

Substance—A chemical.

**Systemic effects**—Systemic toxicity associated with skin absorption of chemicals after exposure of the skin.

## Acknowledgments

This document was developed by the Division of Science Integration (Paul Schulte, Ph.D., Director). Naomi Hudson, Dr.P.H., was the project officer for this document. The basis for this document was a report (*Toxicology Excellence for Risk Assessment [TERA]*) contracted by NIOSH and prepared by Bernard Gadagbui, Ph.D., and Andrew Maier, Ph.D.

Special appreciation is expressed to the following individuals for serving as independent, external reviewers:

- Shane Que Hee, Ph.D., Professor, Environmental Health Sciences Director, UCLA Industrial Hygiene Program Director, UCLA Fielding School of Public Health, Los Angeles, CA
- M. Cecilia Aguila, D.V.M., Division of Human Food Safety, FDA, Center for Veterinary Medicine, Rockville, MD

Special appreciation is expressed to the following individuals for serving as internal reviewers by use of an Intergovernmental Personnel Agreement:

- Ronald E. Baynes, D.V.M., Ph.D., College of Veterinary Medicine, North Carolina State University, Raleigh, NC
- Youcheng Liu, M.D., Sc.D., M.P.H., M.S., University of North Texas Health Science Center, Fort Worth, TX

The following individuals contributed to the development or improvement of the skin notation profiles:

- G. Frank Gerberick, Ph.D., The Procter and Gamble Company, Cincinnati, OH
- Dori Germolec, Ph.D., National Toxicology Program, National Institute for Environmental Health Sciences, Research Triangle, NC
- Ben Hayes, M.D., Ph.D., Division of Dermatology, Vanderbilt School of Medicine, Nashville, TN
- Jennifer Sahmel, M.Sc., CIH, ChemRisk, Boulder, CO
- James Taylor, M.D., Industrial Dermatology, The Cleveland Clinic, Cleveland, OH

This page intentionally left blank.

## **1** Introduction

### 1.1 General Substance Information

Chemical: Cyclohexanol

CAS No: 108-93-0

Molecular weight (MW): 100.2

Molecular formula: C<sub>6</sub>H<sub>11</sub>OH

Structural formula:




Image: National Center for Biotechnology Information [2020]

### 1.2 Purpose

This skin notation profile presents (1) a brief summary of epidemiological and toxicological data associated with skin contact with cyclohexanol and (2) the rationale behind the hazard-specific skin notation (SK) assignment for cyclohexanol. The SK assignment is based on the scientific rationale and logic outlined in the Current Intelligence Bulletin (CIB) 61: A Strategy for Assigning New NIOSH Skin Notations [NIOSH 2009]. The summarized information and health hazard assessment are limited to an evaluation of the potential health effects of dermal exposure to cyclohexanol. A search of all available relevant literature was conducted through January 2020 to identify information on cyclohexanol dermal absorption, acute toxicity, repeated-dose systemic toxicity, carcinogenicity, biological system/ function specific effects (including reproductive

**Synonyms:** Anol, Cyclohexyl alcohol, Hexahydrophenol, Hexalin, Hydralin, Hydroxycyclohexane

**Uses:** With a melting point of 25.93 °C, cyclohexanol can be a solid or a viscous liquid at 25 °C. Some producers use a mixture containing 2.25% methanol to keep cyclohexanol in a liquid state [HSDB 2011]. Cyclohexanol is used primarily as a chemical intermediate in the manufacturing of nylon, as a stabilizer, and a homogenizer for soap and detergent; an estimated >500 to 1 billion pounds (390 million kilograms) of the substance was produced in 2002 [HSDB 2019].

and developmental effects and immunotoxicity), irritation, and sensitization. Information was considered from studies in humans, animals, or appropriate modeling systems that are relevant to assessing the effects of dermal exposure to cyclohexanol. The criteria for the search strategy, evaluation, and selection of data are described in Appendix E in the aforementioned *CIB* 61 [NIOSH 2009].

### 1.3 Overview of SK Assignment

Cyclohexanol is potentially capable of causing numerous adverse health effects following skin contact. A critical review of available data has resulted in the following SK assignment for cyclohexanol: **SK: SYS-DIR (IRR)**. Table 1 provides an overview of the critical effects and data used to develop the SK assignment for cyclohexanol.

Skin notation	Critical effect	Available data
SK: SYS	Central nervous and/or peripheral system effects (tremors, narcosis, hypothermia); acute toxicity	Sufficient animal data
SK: DIR(IRR)	Skin irritancy	Sufficient animal data

Table 1. Summary of the SK assignment for cyclohexanol

## 2 Systemic Toxicity from Skin Exposure (SK: SYS)

No in vivo or in vitro toxicokinetic studies were identified in humans or animals that evaluated dermal exposure to cyclohexanol. Walker et al. [2003] estimated a skin absorption rate of 6.10  $\times 10^{-3}$  centimeters per hour (cm/h) for cyclohexanol based on a quantitative structure-activity relationship prediction. The potential of cyclohexanol to pose a skin absorption hazard was also evaluated using the NIOSH [2009] predictive algorithm for estimating and evaluating the health hazards of dermal exposure to chemical substances. Based on this algorithm, the ratio of skin dose to inhalation dose (the SI ratio) of 0.34 was calculated for cyclohexanol. An SI ratio of  $\geq 0.1$  indicates that skin absorption may significantly contribute to the overall body burden of a substance [NIOSH 2009]; therefore, cyclohexanol is considered to be a skin absorption hazard following dermal exposure.

No estimated dermal lethal dose  $(LD_{Lo})$  in humans was identified. The dermal  $LD_{50}$  (lethal dose in 50% of exposed animals) values in rabbits were reported to be greater than 501 milligrams per kilogram body weight (mg/ kg) but less than 794 mg/kg [Monsanto 1978]. Because the reported acute dermal  $LD_{50}$  value for rabbits is lower than the critical dermal  $LD_{50}$ value of 2,000 mg/kg that identifies chemical substances with the potential for acute dermal toxicity [NIOSH 2009], cyclohexanol is considered acutely toxic following dermal exposure.

No epidemiological studies, human case reports, or subchronic/chronic toxicity studies in animals were identified that evaluated the potential of cyclohexanol to cause systemic effects following dermal exposure. Treon et al. [1943] applied 10 milliliters (mL) (in two 5 mL portions at 0.5hour intervals) of cyclohexanol for one hour a day for 10 days to the clipped abdominal skin of rabbits. Treon et al. [1943] reported that the second and successive dose of cyclohexanol resulted in narcosis, central nervous system effects such as tremor, athetoid movement (inability to maintain body parts in a stable position), and hypothermia, which became more marked with successive exposures. Hypothermia and narcosis were observed in rabbits that received 35 to 130 mL (approximately 29 to 130 grams/animal) of cyclohexanol applied to the clipped skin of the abdomen in 5-mL portions at 20-minute intervals for a total of 160 minutes to 9 hours, in addition to involuntary jerking and twitching of the forelegs and chest muscles in the rabbit given the highest dose. The animals receiving the highest dose of cyclohexanol died [Treon et al. 1943]. These results indicate that high doses of liquid cyclohexanol applied to the skin can result in tremors, narcosis, hypothermia, and death.

No standard toxicity or specialty studies were identified that evaluated biological system/ function specific effects (including reproductive and developmental effects and immunotoxicity) following dermal exposure to cyclohexanol.

No epidemiological studies or animal studies were identified that evaluated the potential of cyclohexanol to be a carcinogen following dermal exposure. Table 2 summarizes the carcinogenic designations of multiple governmental and nongovernmental organizations for cyclohexanol.

Organization	Carcinogenic designation
NIOSH [2005]	No designation
NTP [2014]	No designation
US EPA [2020]*	No designation
European Parliament [2008]	No GHS designation
IARC [2012]	No designation
ACGIH* [2001]	No designation

## Table 2. Summary of the carcinogenic designations for cyclohexanolby governmental and nongovernmental organizations

ACGIH<sup>\*</sup> = American Conference of Governmental Industrial Hygienists; GHS = Globally Harmonized System for Classification and Labelling of Chemicals; IARC = International Agency for Research on Cancer; NIOSH = National Institute for Occupational Safety and Health; NTP = National Toxicology Program; US EPA = United States Environmental Protection Agency. \*Date accessed

Although no toxicokinetic data were identified that estimated the percent dermal absorption of cyclohexanol in humans or animals, the mathematical model predicts that cyclohexanol may be absorbed through the skin following dermal exposure. Acute and repeat-dose [Monsanto 1978; Treon et al. 1943] toxicity studies with rabbits provide limited data indicating that cyclohexanol can be absorbed through the skin and may be acutely toxic and produce central nervous and/or peripheral nervous systems effects (tremors, narcosis, hypothermia) including death at high doses. Therefore, this assessment assigns a skin notation of SK: SYS for cyclohexanol.

### 3 Direct Effects on Skin (SK: DIR)

No human or animal *in vivo* studies on corrosivity or *in vivo* tests for corrosivity using human or animal skin models or *in vitro* tests of skin integrity using cadaver skin were identified. Limited skin irritation tests were identified in animals for cyclohexanol. Mild irritation was observed at 24 and 72 hours in a skin irritation test after 0.5 mL of undiluted cyclohexanol was applied to the skin of rabbits for 24 hours [Monsanto 1978]. Skin began to flake off after seven to ten days, but there was no corrosivity reported [Monsanto 1978]. Smyth et al. [1962] also reported mild irritation to following application of cyclohexanol to

clipped rabbit skin, with an irritation score of 2 out of 6 (where 1 is no irritation and 6 is necrosis). Repeated cutaneous application of cyclohexanol at high doses (10 mL of cyclohexanol for 10 days for a total of 94.4 g/kg) to the skin of rabbits resulted in slight local erythema, localized ulcers, and thickening of the skin [Treon et al. 1943]. Animals that received smaller doses of cyclohexanol (35-130 mL) experienced local erythema of the skin [Treon et al. 1943].

Using human keratinocytes, Muller-Decker et al. [1994] measured *in vitro* proinflammatory eicosanoid and interleukin 1-alpha (IL-1 $\alpha$ ) release as indicators of skin irritancy. Cyclohexanol was observed to induce a delayed (greater than 4 hour) stimulation of arachidonic acid release, leading the authors to estimate a half-maximum stimulation concentration (SC<sub>50</sub>) of 2.8 to 3.2 x 10<sup>-2</sup> molar (M). A 10-fold stimulatory (ED<sub>10</sub>) concentration of IL-1 $\alpha$  was observed at a dose of 5.3 x 10<sup>-2</sup> M of cyclohexanol [Muller-Decker et al. 1994]. These mechanistic studies support the in vivo studies that suggest that cyclohexanol has the potential to cause skin irritation.

The structure activity relationship model, DEREK<sup>®</sup>, predicted cyclohexanol to be negative

<sup>&</sup>lt;sup>\*</sup>References in **bold** text indicate studies that serve as the basis of the SK assignments.

for skin irritation, indicating that the chemical does not have structural alerts for skin irritation.

Although DEREK<sup>®</sup> predicted cyclohexanol to be negative for skin irritation, skin irritation tests in rabbits [**Treon et al. 1943; Smyth et al. 1962; Monsanto 1978**] and the *in vitro* data using human keratinocytes [**Muller-Decker et al. 1994**] indicate that cyclohexanol has the potential to cause mild skin irritation, including localized ulcers and thickening of the skin at high doses. Therefore, this assessment assigns an SK: DIR(IRR) notation for cyclohexanol.

## 4 Immune-mediated Responses (SK: SEN)

No occupational exposure studies or diagnostic patch tests in humans or predictive tests (guinea pig maximization tests, Buehler test, murine local lymph node assays, etc.) that evaluated the potential of the cyclohexanol to cause skin sensitization were identified. The structure activity relationship model, DEREK<sup>®</sup>, predicted cyclohexanol to be negative for skin sensitization, indicating that the chemical does not have structural alerts for skin sensitization.

Lack of case reports or diagnostic patch tests in humans or predictive tests in animals precludes adequate evaluation of the skin sensitization potential of cyclohexanol. Therefore, this assessment does not assign an SK: SEN notation for cyclohexanol.

## 5 Summary

Although no toxicokinetic data were identified that estimated the percent dermal absorption of cyclohexanol in humans or animals, the mathematical model predicts that cyclohexanol may be absorbed through the skin following dermal exposure. Acute and repeat-dose [Monsanto 1978; Treon et al. 1943] toxicity studies with rabbits provide limited data indicating that cyclohexanol can be absorbed through the skin and may be acutely toxic and produce central nervous and/or peripheral nervous systems effects (tremors, narcosis, hypothermia), including death at high doses. Results from a skin irritation test in rabbits [Smyth et al. 1962; Monsanto 1978] and in vitro data using human keratinocytes [Muller-Decker et al. 1994] provide evidence that cyclohexanol has the potential to cause skin irritation, including the potential to cause localized ulcers and thickening of the skin at high doses. No case reports or diagnostic patch tests in humans or predictive tests in animals were identified upon which the skin sensitization potential of cyclohexanol can be evaluated. Therefore, this assessment assigns a composite skin notation of SK: SYS-DIR (IRR) for cyclohexanol.

Table 3 summarizes the skin hazard designations for cyclohexanol issued by NIOSH and other organizations. The equivalent dermal designation for cyclohexanol according to the Globally Harmonized System (GHS) of classification and labeling of chemicals is Skin

Table 3. Summary of the previously issued skin hazard designations for
cyclohexanol from NIOSH and other organizations

Organization	Skin hazard designation
NIOSH [2005]	[skin]: Based on the potential for dermal absorption
OSHA [2018]*	No designation
ACGIH* [2001]	[skin] Based on the studies with rabbits in which narcosis, tremors, hypothermia, and death ensued following dermal application of cyclohexanol

ACGIH<sup>\*</sup> = American Conference of Governmental Industrial Hygienists; NIOSH = National Institute for Occupational Safety and Health; OSHA = Occupational Safety and Health Administration.

\*Year accessed.

Irritation Category 2 (Causes skin irritation) [European Parliament 2008].

### References

**Note**: Asterisks (\*) denote sources cited in text; daggers (†) denote additional resources.

- \*ACGIH\* [2001]. Documentation of threshold limit values and biological exposure indices. 7th Ed. Cincinnati, OH: American Conference of Governmental Industrial Hygienists.
- †Clayton GD, Clayton FE, eds [1981–1982]. Patty's industrial hygiene and toxicology, volumes 2A, 2B, 2C: toxicology. 3rd ed. New York: John Wiley Sons, p. 4646.
- †Draize JH, Alvarez E, Whitesell MF, Woodard G, Hagan EC, Nelson AA [1948]. Toxicological investigations of compounds proposed for use as insect repellents. A. Local and systemic effects following topical skin application. B. Acute oral toxicity. C. Pathological examination. J Pharmacol Exper Therapeutics 93:26–39.
- †Epstein WL [1974]. Report to RIFM. Woodcliff Lake, NJ: Research Institute for Fragrance Materials.
- \*ECHA [2020]. Classification and labelling inventory: table of harmonised entries in Annex VI to CLP. European Chemicals Agency, https:// pubchem.ncbi.nlm.nih.gov/compound/7966. Accessed 01-21-2020.
- \*HSDB [2011]. Cyclohexanol. In: Hazardous Substances Data Bank, https://pubchem.ncbi.nlm. nih.gov/compound/7966. Accessed: 06-07-19.
- \*IARC [2012]. Agents reviewed by the IARC monographs. In: IARC monographs on the evaluation of carcinogenic risks to humans. Lyon, France: World Health Organization, International Agency for Research on Cancer, https://monographs.iarc. fr/monographs-available/. Accessed 12-06-17.
- †Mraz J, Galova E, Nohova H, Vitkova D [1994]. Uptake, metabolism and elimination of cyclohexanone in humans. Intl Arch Occup Environ Health 66(3):203–208.
- \*Monsanto Company [1978]. Toxicity studies on cyclohexanol. South Windsor, CT: Younger Laboratories, OTS 0538617.
- \*Muller-Decker K, Furstenberger G, Marks F [1994]. Keratinocyte-derived proinflammatory key mediators and cell viability as in vitro parameters of irritancy: a possible alternative to the Draize skin irritation test. Toxicol Appl Pharmacol 127: 99–108.
- \*National Center for Biotechnology Information [2020]. PubChem Database. Cyclohexanol, CID=7966, https://pubchem.ncbi.nlm.nih.

gov/compound/Cyclohexanol. Accessed on 01-22-2020.

- \*NIOSH [2005]. NIOSH pocket guide to chemical hazards. Cincinnati, OH: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, DHHS (NIOSH) Publication No. 2005–149, https:// www.cdc.gov/niosh/npg/. Accessed 01-28-2020.
- \*NIOSH [2009]. Current intelligence bulletin 61: a strategy for assigning the new NIOSH skin notations for chemicals. Cincinnati, OH: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, DHHS (NIOSH) Publication No. 2005-149, https://www.cdc.gov/niosh/docs/2009-147/ pdfs/2009-147.pdf. Accessed 01-28-2020.
- \*NTP [2014]. Report on carcinogens, 13th edition. Research Triangle, NC: U.S. Department of Health and Human Services, Public Health Service. National Toxicology Program, https:// ntp.niehs.nih.gov/whatwestudy/assessments/ cancer/roc/index.html. Accessed 01-22-2020.
- \*OSHA [2018]. Cyclohexanol. In: OSHA occupational chemical database. Washington, DC: Occupational Safety and Health Administration, https://www.osha.gov/chemicaldata/chemResult.html?recNo=92. Accessed 01-22-2020.
- †Schroder J [1986]. Cutaneous absorption of chemicals. OORSIG 57:169–176.
- \*Smyth HP Jr, Carpenter CP, Weil CS, Pozzani UC, Striegel JA [1962]. Range-finding toxicity data: List VI. Am Ind Hyg Assoc J *23*:95–107.
- †Takeuchi A, Ogawa Y, Endo Y, Kawai T, Namera A, Yamamuro K, Sumino K, Endo G [2015]. Evaluation of urinary cyclohexanediols and cyclohexanol as biomarkers of occupational exposure to cyclohexane. J Occup Health 57(4):365–370.
- \*Treon JF, Crutchfield WE, Kitzmiller KV [1943]. The physiological response of rabbits to cyclohexane, methylcyclohexane, and certain derivatives of these compounds. I. Oral administration and cutaneous application. J Ind Hyg Toxicol J 25(6):199–214.
- \*US EPA (United States Environmental Protection Agency) [ND]. Integrated Risk Information System. Washington, DC: United States Environmental Protection Agency, https://www.epa. gov/iris. Accessed 01-21-2020.
- \*Walker JD, Rodford R, Patlewicz G [2003]. Quantitative structure-activity relationships for predicting percutaneous absorption rates. 22:1870–1884.

## **Appendix: Calculation of the SI Ratio for Cyclohexanol**

This appendix presents an overview of the SI ratio and a summary of the calculation of the SI ratio for cyclohexanol. Although the SI ratio is considered in the determination of a substance's hazard potential following skin contact, it is intended only to serve as supportive data during the assignment of the NIOSH SK. An in-depth discussion on the rationale and calculation of the SI ratio can be found in Appendix B of the *Current Intelligence Bulletin (CIB)* 61: A Strategy for Assigning New NIOSH Skin Notations [NIOSH 2009].

### **Overview**

The SI ratio is a predictive algorithm for estimating and evaluating the health hazards of skin exposure to substances. The algorithm is designed to evaluate the potential for a substance to penetrate the skin and induce systemic toxicity [NIOSH 2009]. The goals for incorporating this algorithm into the proposed strategy for assigning SYS notation are as follows:

- Provide an alternative method to evaluate substances for which no clinical reports or animal toxicity studies exist or for which empirical data are insufficient to determine systemic effects.
- 2. Use the algorithm evaluation results to determine whether a substance poses a skin absorption hazard and should be labeled with the SYS notation.

The algorithm evaluation includes three steps:

- determining a skin permeation coefficient (*k<sub>p</sub>*) for the substance of interest,
- 2. estimating substance uptake by the skin and respiratory absorption routes, and
- 3. evaluating whether the substance poses a skin exposure hazard.

The algorithm is flexible in the data requirement and can operate entirely on the basis of the physicochemical properties of a substance and the relevant exposure parameters. Thus, the algorithm is independent of the need for biologic data. Alternatively, it can function with both the physicochemical properties and the experimentally determined permeation coefficient when such data are available and appropriate for use.

The first step in the evaluation is to determine the  $k_p$  for the substance to describe the transdermal penetration rate of the substance [NIOSH 2009]. The  $k_p$ , which represents the overall diffusion of the substance through the stratum corneum and into the blood capillaries of the dermis, is estimated from the compound's molecular weight (*MW*) and base-10 logarithm of its octanol–water partition coefficient (log K<sub>OW</sub>). In this example,  $k_p$  is determined for a substance with use of Equation 1. A self-consistent set of units must be used, such as centimeters per hour (cm/hr), outlined in Table A1. Other model-based estimates of  $k_p$  may also be used [NIOSH 2009].

### Equation 1: Calculation of Skin Permeation Coefficient ( $k_{aq}$ )

$$k_p = \frac{1}{\frac{1}{k_{psc} + k_{pol}} + \frac{1}{k_{aq}}}$$

where  $k_{psc}$  is the permeation coefficient in the lipid fraction of the stratum corneum,  $k_{pol}$  is the coefficient in the protein fraction of the stratum corneum, and  $k_{aq}$  is the coefficient in the watery epidermal layer. These components are individually estimated by

$$\log k_{psc} = -1.326 + (0.6097 \times \log K_{ow}) - (0.1786 \times MW^{0.5})$$
$$k_{pol} = 0.0001519 \times MW^{-0.5}$$
$$k_{aa} = 2.5 \times MW^{-0.5}$$

The second step is to calculate the biologic mass uptake of the substance from skin absorption (skin dose) and inhalation (inhalation dose) during the same period of exposure. The skin dose is calculated as a mathematical product of the  $k_p$ , the water solubility ( $S_W$ ) of the substance, the exposed skin surface area, and the duration of exposure. Its units are milligrams (mg). Assume that the skin exposure

continues for 8 hours to unprotected skin on the palms of both hands (a surface area of 360 square centimeters [cm<sup>2</sup>]).

### **Equation 2: Determination of Skin Dose**

Skin dose =  $k_p \times S_w \times$  Exposed skin surface area × Exposure time =  $k_p (cm/hr) \times S_w (mg/cm^3) \times$ 360 cm<sup>2</sup> × 8 hr

The inhalation dose (in mg) is derived on the basis of the occupational exposure limit (OEL) of the substance—if the OEL is developed to prevent the occurrence of systemic effects rather than sensory/irritant effects or direct effects on the respiratory tract. Assume a continuous exposure of 8 hours, an inhalation volume of 10 cubic meters (m<sup>3</sup>) inhaled air in 8 hours, and a factor of 75% for retention of the airborne substance in the lungs during respiration (retention factor, or RF).

#### **Equation 3: Determination of Inhalation Dose**

Inhalation dose = OEL × Inhalation volume × RF = OEL (mg/m<sup>3</sup>) × 10 m<sup>3</sup> × 0.75

The final step is to compare the calculated skin and inhalation doses and to present the result as a ratio of skin dose to inhalation dose (the SI ratio). This ratio quantitatively indicates (1) the significance of dermal absorption as a route of occupational exposure to the substance and (2) the contribution of dermal uptake to systemic toxicity. If a substance has an SI ratio greater than or equal to 0.1, it is considered a skin absorption hazard.

### Calculation

Table A1 summarizes the data applied in the previously described equations to determine the SI ratio for cyclohexanol. The calculated SI ratio was 0.34. On the basis of these results, cyclohexanol is predicted to represent a skin absorption hazard.

### Appendix References

- Hayes WA [2008]. Principles and methods of toxicology. 5th ed. New York: Informa Healthcare USA.
- NIOSH [2005]. NIOSH pocket guide to chemical hazards. Cincinnati, OH: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, DHHS (NIOSH) Publication No. 2005–149, https:// www.cdc.gov/niosh/npg/. Accessed 01-28-2020.
- NIOSH [2009]. Current intelligence bulletin 61: a strategy for assigning new NIOSH skin notations. Cincinnati, OH: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, DHHS (NIOSH) Publication No. 2009-147, https://www.cdc.gov/niosh/docs/2009-147/pdfs/2009-147.pdf. Accessed 01-28-2020.
- NLM [ND]. Toxnet, ChemIDplus: cyclohexanol. Bethesda, MD: National Institutes of Health, National Library of Medicine, https://chem. nlm.nih.gov/chemidplus/rn/108-93-0. Accessed 01-28-2020.

#### Variables used in calculation Units Value Skin permeation coefficient Permeation coefficient of stratum corneum lipid path ( $k_{psc}$ ) cm/hr 0.0043 Permeation coefficient of the protein fraction of the cm/hr $1.5178 \times 10^{-5}$ stratum corneum $(k_{pol})$ Permeation coefficient of the watery epidermal layer $(k_{aq})$ cm/hr 0.2498 Molecular weight (MW)\* amu 100.16 Base-10 logarithm of its octanol-water partition coefficient None 1.23 $(Log K_{ow})^*$ Calculated skin permeation coefficient $(k_{\nu})$ cm/hr 0.00427 Skin dose mg/cm<sup>3</sup> Water solubility $(S_w)^*$ 42 Calculated skin permeation coefficient $(k_p)$ cm/hr 0.00427 Estimated skin surface area (palms of hands)<sup>§</sup> cm<sup>2</sup> 360 Exposure time hr 8 Calculated skin dose 516.21 mg Inhalation dose Occupational exposure limit (OEL)<sup>†</sup> mg/m<sup>3</sup> 200 Inhalation volume m<sup>3</sup> 10 Retention factor (RF) None 0.75 Inhalation dose 1500 mg

### Table A1. Summary of data used to calculate the SI ratio for cyclohexanol

\*Variables identified from NLM [ND].

Skin dose-to-inhalation dose (SI) ratio

<sup>†</sup>The OEL used in calculation of the SI ratio for cyclohexanol was the NIOSH recommended exposure limit (REL) [NIOSH 2005]. <sup>s</sup>Hayes WA [2008]. Principles and methods of toxicology. 5th ed. New York: Informa Healthcare USA.

None

0.3441

This page intentionally left blank.



Promoting productive workplaces through safety and health research

DHHS (NIOSH) Publication No. 2021-101 DOI: https://doi.org/10.26616/NIOSHPUB2021101